Emerging drugs for autonomic dysfunction in Parkinson's disease

Autores
Pérez Lloret, Santiago; Rey, Verónica; Pavy-Le Traon, Anne; Rascol, Olivier
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión enviada
Descripción
Fil: Pérez Lloret, Santiago. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia
Fil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina. Laboratorio de Clínica Farmacológica y Epidemiología; Argentina
Fil: Rey, Verónica. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia
Fil: Rey, Verónica. Pontificia Universidad Católica Argentina. Laboratorio de Clínica Farmacológica y Epidemiología; Argentina
Fil: Pavy-Le Traon, Anne. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia
Fil: Rascol, Olivier. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia
Abstract: Autonomic dysfunction, including orthostatic hypotension (OH), sialorrhea, sexual dysfunction, urinary dysfunction and constipation is a common feature of Parkinson’s disease (PD). Even though its treatment has been recognized as a major unmet need in PD, there is a paucity of clinical trials to assess their treatment. Areas covered: Evidence about the efficacy and safety of available treatments for autonomic dysfunction is summarized. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of each disorder in PD. Proof-of-concept trials and circumstantial evidence about treatments for autonomic dysfunction as well as upcoming clinical trials are discussed. Finally, critical aspects of clinical trials design are considered. Expert opinion: Botulinum toxin (BTX) or glycopyrrolate might be used for sialorrhea whereas macrogol could be useful in constipation. There is preliminary evidence suggesting that fludrocortisone, domperidone, droxidopa or fipamezole may be effective for the treatment of OH. Tropicamide, clonidine or radiotherapy are under development for sialorrhea. Sildenafil may be effective for the treatment of erectile dysfunction; BTX or behavioral therapy for urinary incontinence and lubiprostone and probiotics for constipation. Sound clinical trials are needed in order to allow firm evidence-based recommendations about these treatments
Fuente
Preprint del documento publicado en Expert Opinion on Emerging Drugs, Vol. 18, Nro. 1, 2013
Materia
TOXINA BOTULIMICA
ESTREÑIMIENTO
DOMPERIDONA
DROXIDOPA
DISFUNCION ERECTIL
FLUDROCORTISONA
INCONTINENCIA
HIPOTENSION ORTOSTATICA
ENFERMEDAD DE PARKINSON
DISFUNCION URINARIA
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
Repositorio Institucional (UCA)
Institución
Pontificia Universidad Católica Argentina
OAI Identificador
oai:ucacris:123456789/1667

id RIUCA_90e72abf960eec6b7294c344613795af
oai_identifier_str oai:ucacris:123456789/1667
network_acronym_str RIUCA
repository_id_str 2585
network_name_str Repositorio Institucional (UCA)
spelling Emerging drugs for autonomic dysfunction in Parkinson's diseasePérez Lloret, SantiagoRey, VerónicaPavy-Le Traon, AnneRascol, OlivierTOXINA BOTULIMICAESTREÑIMIENTODOMPERIDONADROXIDOPADISFUNCION ERECTILFLUDROCORTISONAINCONTINENCIAHIPOTENSION ORTOSTATICAENFERMEDAD DE PARKINSONDISFUNCION URINARIAFil: Pérez Lloret, Santiago. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; FranciaFil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina. Laboratorio de Clínica Farmacológica y Epidemiología; ArgentinaFil: Rey, Verónica. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; FranciaFil: Rey, Verónica. Pontificia Universidad Católica Argentina. Laboratorio de Clínica Farmacológica y Epidemiología; ArgentinaFil: Pavy-Le Traon, Anne. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; FranciaFil: Rascol, Olivier. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; FranciaAbstract: Autonomic dysfunction, including orthostatic hypotension (OH), sialorrhea, sexual dysfunction, urinary dysfunction and constipation is a common feature of Parkinson’s disease (PD). Even though its treatment has been recognized as a major unmet need in PD, there is a paucity of clinical trials to assess their treatment. Areas covered: Evidence about the efficacy and safety of available treatments for autonomic dysfunction is summarized. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of each disorder in PD. Proof-of-concept trials and circumstantial evidence about treatments for autonomic dysfunction as well as upcoming clinical trials are discussed. Finally, critical aspects of clinical trials design are considered. Expert opinion: Botulinum toxin (BTX) or glycopyrrolate might be used for sialorrhea whereas macrogol could be useful in constipation. There is preliminary evidence suggesting that fludrocortisone, domperidone, droxidopa or fipamezole may be effective for the treatment of OH. Tropicamide, clonidine or radiotherapy are under development for sialorrhea. Sildenafil may be effective for the treatment of erectile dysfunction; BTX or behavioral therapy for urinary incontinence and lubiprostone and probiotics for constipation. Sound clinical trials are needed in order to allow firm evidence-based recommendations about these treatmentsTaylor and Francis2013info:eu-repo/semantics/articleinfo:eu-repo/semantics/submittedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/166710.1517/14728214.2013.766168Pérez Lloret, S., et al. Emerging drugs for autonomic dysfunction in Parkinson's disease [en línea]. Preprint del documento publicado en Expert Opinion on Emerging Drugs. 2013, 18 (1). doi:10.1517/14728214.2013.766168. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1667Preprint del documento publicado en Expert Opinion on Emerging Drugs, Vol. 18, Nro. 1, 2013reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Católica Argentinaengenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/2025-07-03T10:55:21Zoai:ucacris:123456789/1667instacron:UCAInstitucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852025-07-03 10:55:21.964Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentinafalse
dc.title.none.fl_str_mv Emerging drugs for autonomic dysfunction in Parkinson's disease
title Emerging drugs for autonomic dysfunction in Parkinson's disease
spellingShingle Emerging drugs for autonomic dysfunction in Parkinson's disease
Pérez Lloret, Santiago
TOXINA BOTULIMICA
ESTREÑIMIENTO
DOMPERIDONA
DROXIDOPA
DISFUNCION ERECTIL
FLUDROCORTISONA
INCONTINENCIA
HIPOTENSION ORTOSTATICA
ENFERMEDAD DE PARKINSON
DISFUNCION URINARIA
title_short Emerging drugs for autonomic dysfunction in Parkinson's disease
title_full Emerging drugs for autonomic dysfunction in Parkinson's disease
title_fullStr Emerging drugs for autonomic dysfunction in Parkinson's disease
title_full_unstemmed Emerging drugs for autonomic dysfunction in Parkinson's disease
title_sort Emerging drugs for autonomic dysfunction in Parkinson's disease
dc.creator.none.fl_str_mv Pérez Lloret, Santiago
Rey, Verónica
Pavy-Le Traon, Anne
Rascol, Olivier
author Pérez Lloret, Santiago
author_facet Pérez Lloret, Santiago
Rey, Verónica
Pavy-Le Traon, Anne
Rascol, Olivier
author_role author
author2 Rey, Verónica
Pavy-Le Traon, Anne
Rascol, Olivier
author2_role author
author
author
dc.subject.none.fl_str_mv TOXINA BOTULIMICA
ESTREÑIMIENTO
DOMPERIDONA
DROXIDOPA
DISFUNCION ERECTIL
FLUDROCORTISONA
INCONTINENCIA
HIPOTENSION ORTOSTATICA
ENFERMEDAD DE PARKINSON
DISFUNCION URINARIA
topic TOXINA BOTULIMICA
ESTREÑIMIENTO
DOMPERIDONA
DROXIDOPA
DISFUNCION ERECTIL
FLUDROCORTISONA
INCONTINENCIA
HIPOTENSION ORTOSTATICA
ENFERMEDAD DE PARKINSON
DISFUNCION URINARIA
dc.description.none.fl_txt_mv Fil: Pérez Lloret, Santiago. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia
Fil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina. Laboratorio de Clínica Farmacológica y Epidemiología; Argentina
Fil: Rey, Verónica. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia
Fil: Rey, Verónica. Pontificia Universidad Católica Argentina. Laboratorio de Clínica Farmacológica y Epidemiología; Argentina
Fil: Pavy-Le Traon, Anne. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia
Fil: Rascol, Olivier. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia
Abstract: Autonomic dysfunction, including orthostatic hypotension (OH), sialorrhea, sexual dysfunction, urinary dysfunction and constipation is a common feature of Parkinson’s disease (PD). Even though its treatment has been recognized as a major unmet need in PD, there is a paucity of clinical trials to assess their treatment. Areas covered: Evidence about the efficacy and safety of available treatments for autonomic dysfunction is summarized. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of each disorder in PD. Proof-of-concept trials and circumstantial evidence about treatments for autonomic dysfunction as well as upcoming clinical trials are discussed. Finally, critical aspects of clinical trials design are considered. Expert opinion: Botulinum toxin (BTX) or glycopyrrolate might be used for sialorrhea whereas macrogol could be useful in constipation. There is preliminary evidence suggesting that fludrocortisone, domperidone, droxidopa or fipamezole may be effective for the treatment of OH. Tropicamide, clonidine or radiotherapy are under development for sialorrhea. Sildenafil may be effective for the treatment of erectile dysfunction; BTX or behavioral therapy for urinary incontinence and lubiprostone and probiotics for constipation. Sound clinical trials are needed in order to allow firm evidence-based recommendations about these treatments
description Fil: Pérez Lloret, Santiago. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia
publishDate 2013
dc.date.none.fl_str_mv 2013
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/submittedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str submittedVersion
dc.identifier.none.fl_str_mv https://repositorio.uca.edu.ar/handle/123456789/1667
10.1517/14728214.2013.766168
Pérez Lloret, S., et al. Emerging drugs for autonomic dysfunction in Parkinson's disease [en línea]. Preprint del documento publicado en Expert Opinion on Emerging Drugs. 2013, 18 (1). doi:10.1517/14728214.2013.766168. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1667
url https://repositorio.uca.edu.ar/handle/123456789/1667
identifier_str_mv 10.1517/14728214.2013.766168
Pérez Lloret, S., et al. Emerging drugs for autonomic dysfunction in Parkinson's disease [en línea]. Preprint del documento publicado en Expert Opinion on Emerging Drugs. 2013, 18 (1). doi:10.1517/14728214.2013.766168. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1667
dc.language.none.fl_str_mv eng
eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Taylor and Francis
publisher.none.fl_str_mv Taylor and Francis
dc.source.none.fl_str_mv Preprint del documento publicado en Expert Opinion on Emerging Drugs, Vol. 18, Nro. 1, 2013
reponame:Repositorio Institucional (UCA)
instname:Pontificia Universidad Católica Argentina
reponame_str Repositorio Institucional (UCA)
collection Repositorio Institucional (UCA)
instname_str Pontificia Universidad Católica Argentina
repository.name.fl_str_mv Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentina
repository.mail.fl_str_mv claudia_fernandez@uca.edu.ar
_version_ 1836638330863747072
score 13.13397